Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TLR4 | O00206 | 10/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22033844 | 0.96 | LMNA (0.44) | LMNATLR4KMT2ALY96POLB | |
| SCHEMBL23872029 | 0.92 | LMNA (0.42) | LMNATLR4KMT2ALY96POLB | |
| SCHEMBL23651844 | 0.87 | LMNA (0.48) | LMNATLR4KMT2ALY96POLB | |
| SCHEMBL23651830 | 0.87 | LMNA (0.48) | LMNATLR4KMT2ALY96POLB | |
| SCHEMBL24105787 | 0.87 | LMNA (0.48) | LMNATLR4KMT2ALY96POLB | |
| SCHEMBL17772563 | 0.87 | LMNA (0.48) | LMNATLR4KMT2ALY96POLB | |
| SCHEMBL22033880 | 0.86 | CYP2D6 (0.39) | LMNAKMT2AMAPTCYP2C9CA12 | |
| SCHEMBL22033953 | 0.86 | CYP2D6 (0.39) | LMNAKMT2AMAPTCYP2C9CA12 | |
| SCHEMBL22033978 | 0.86 | CYP2D6 (0.39) | LMNAKMT2AMAPTCYP2C9CA12 | |
| SCHEMBL22033950 | 0.86 | CYP2D6 (0.39) | LMNAKMT2AMAPTCYP2C9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3890721-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | Flagship Pioneering Innovations V, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210299079-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2020118178-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299079-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | SLC16A1, SLC16A3, SLC16A8 | LMNA 1443/4885TLR4 427/4885KMT2A 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.